Pfizer Inc. (PFE) said, in 2021, the company exceeded its goal of manufacturing 3 billion doses of Comirnaty, the Pfizer-BioNTech COVID-19 vaccine. Looking forward, the company increased its 2022 revenue guidance for Comirnaty, reflecting doses expected to be delivered under supply contracts signed as of late-January. Also, the company issued fiscal guidance for the coming year which, if achieved, would represent the highest level of annual revenues and adjusted EPS in its history.
Pfizer also issued its long-term expectations for COVID-19. The company said the virus is able to mutate often, making it difficult to stay ahead of it. People can become reinfected by the same or different strains over time, the company noted.
For comments and feedback: editorial@rttnews.com